Yoshifumi Shimizu
Takarazuka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
TARC levels in lenalidomide-induced rash during multiple myeloma treatment
Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology
Published: June 03, 2026
Touch Smear Cytology in Epstein-Barr Virus-Positive Nodal T- and NK-Cell Lymphoma: Cytological Features of This Rare, Aggressive Lymphoma.
Journal: Cytopathology : official journal of the British Society for Clinical Cytology
Published: November 03, 2025
Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma.
Journal: Hematology (Amsterdam, Netherlands)
Published: May 17, 2021
Plateau is a prognostic factor of lenalidomide therapy for previously treated multiple myeloma.
Journal: Hematological oncology
Published: December 08, 2020
Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion.
Journal: Annals of hematology
Published: February 08, 2020
Follicular lymphoma mimicking marginal zone lymphoma in lymph node: a case report.
Journal: International journal of clinical and experimental pathology
Published: August 17, 2014
Diffuse alveolar damage in a patient with Epstein Barr virus (EBV)-positive diffuse large B-cell lymphoma,severely low serum folate, and megaloblastic anemia: a case report of autopsy.
Journal: International journal of clinical and experimental pathology
Published: January 28, 2014
The translation elongation factor eEF2 is a novel tumor‑associated antigen overexpressed in various types of cancers.
Journal: International journal of oncology
Published: December 02, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026